These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 17881538

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.
    Kikuchi K, Akiba T, Nitta K, Masakane I, Ando R, Izumi N, Atsukawa M, Yamazaki C, Kato F, Hotta N, Tominaga Y, Orito E, Hora K, Nagasawa M, Kasahara H, Kawaguchi M, Kimura H, Ikebe N, Kawanishi H, Moriishi M, Shigemoto K, Harada T, Hirakata H, Watanabe H, Nosaki T, Tsubouchi H, Imawari M, Akizawa T.
    Ther Apher Dial; 2014 Dec; 18(6):603-11. PubMed ID: 25196061
    [Abstract] [Full Text] [Related]

  • 3. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW, Wang GQ, Sun LJ, Li XG, Li SC.
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit.
    Covic A, Maftei ID, Mardare NG, Ioniţă-Radu F, Totolici C, Tuţă L, Golea O, Covic M, Volovăţ C, Gusbeth-Tatomir P, Mircescu G.
    J Nephrol; 2006 Jun; 19(6):794-801. PubMed ID: 17173254
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.
    Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiocchi L, Filice G.
    Antivir Ther; 2004 Aug; 9(4):491-7. PubMed ID: 15456079
    [Abstract] [Full Text] [Related]

  • 10. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C.
    Liu CH, Liang CC, Liu CJ, Lin JW, Chen SI, Hung PH, Tsai HB, Lai MY, Chen PJ, Chen DS, Kao JH.
    Clin Infect Dis; 2010 Sep 01; 51(5):541-9. PubMed ID: 20645865
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Peginterferon alfa-2a in patients with chronic hepatitis C.
    Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ.
    N Engl J Med; 2000 Dec 07; 343(23):1666-72. PubMed ID: 11106715
    [Abstract] [Full Text] [Related]

  • 13. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V.
    AIDS; 2008 Jan 02; 22(1):15-21. PubMed ID: 18090387
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection.
    Chan TM, Ho SK, Tang CS, Tse KC, Lam MF, Lai KN, Yung S.
    Nephrology (Carlton); 2007 Feb 02; 12(1):11-7. PubMed ID: 17295655
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Treatment of hepatitis C in hemodialysis patients with pegylated interferon alpha-2a as monotherapy.
    Sikole A, Dzekova P, Selja N, Gaseva M, Nikolov IG, Zabzun M, Muharemi S, Asani A, Amitov V, Mena S, Grunevska V, Ivanovski L, Polenakovic M.
    Ren Fail; 2007 Feb 02; 29(8):961-6. PubMed ID: 18067041
    [Abstract] [Full Text] [Related]

  • 18. Four-week pegylated interferon alpha-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: a pilot, randomized study.
    Tsubota A, Satoh K, Aizawa M, Takamatsu S, Namiki Y, Ohkusa T, Fujise K, Tajiri H.
    World J Gastroenterol; 2008 Dec 21; 14(47):7220-4. PubMed ID: 19084937
    [Abstract] [Full Text] [Related]

  • 19. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Napoli N, Giannelli G, Antonaci A, Antonaci S.
    J Viral Hepat; 2008 Apr 21; 15(4):300-4. PubMed ID: 18307592
    [Abstract] [Full Text] [Related]

  • 20. 48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection.
    Hui CK, Lai LS, Lam P, Zhang HY, Fung TT, Lai ST, Wong WM, Lo CM, Fan ST, Leung N, Lau GK, Hong Kong Liver Fibrosis Study Group.
    Aliment Pharmacol Ther; 2006 Apr 15; 23(8):1171-8. PubMed ID: 16611278
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.